Previous 10 | Next 10 |
The FDA has authorized Sorrento Therapeutics' (NASDAQ:SRNE) IND application for a phase 1b trial of STI-1386 (Seprehvec) for oncolytic virus in patients with relapsed or refractor solid tumors. "Seprehvec allows for locoregional immune stimulation at the tumor site while potentially mini...
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase 1b clinical trial using STI-1386, Seprehvec™, entitled “Dose Escal...
As early lab results on the vaccine effectiveness against the Omicron variant started to emerge, COVID-19 vaccine stocks led by BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) sank this week, dragging the NASDAQ Biotechnology Index (NASDAQ:IBB) for the second consecutive week. However, the h...
Sorrento Therapeutics' (SRNE) subsidiary Scilex Holding Company announces positive top-line results from its SP-102 (SEMDEXA) Phase 3 Trial C.L.E.A.R. Program, a corticosteroid injectable dexamethasone sodium phosphate viscous gel for the treatment of lumbosacral radicular pain, or sciat...
Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announces highly significant positive top-line results from its Phase 3 SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R Program for its novel, non-opioid, corticosteroid formulation, injecta...
A Phase 2 trial of intra-articular RTX for knee OA pain has enrolled its first two patients. The injections were well tolerated and both patients were discharged home after a brief period of observation. Phase 1b data demonstrated significant efficacy supporting RTX as an ideal ca...
SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sorrento’s Clinical Laboratory, located in San Diego, California,...
Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not yet known what risks it poses to public health. G...
Shares of Sorrento Therapeutics (SRNE +6.0%) are modestly higher in afternoon trading after the company announced an order from a large diagnostic laboratory in Brazil for its COVISTIX COVID-19 test. The company said the tests will begin to be delivered by the end of the year. Sorrento says t...
Sorrento has received orders from its logistics partner and a large diagnostic laboratory client for official commercial launch of COVISTIX™ COVID-19 Virus Rapid Antigen Detection Test in Brazil. SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasd...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...